The PSA Test


What is Prostate Specific Antigen (PSA)?

Prostate Specific Antigen (PSA) is a protein produced within the prostate gland and is secreted into seminal fluid.

There are two types of PSA:
  1. Free PSA: moves freely in the blood as it is unbound to other proteins  
  2. Complex PSA: attached to other proteins as it moves around the blood
Free PSA comes from benign prostatic hyperplasia (BPH), an enlargement of the prostate. The higher the amount of free PSA, the less likely prostate cancer will be found as prostate cancer cells produce more complex PSA.


What is the PSA test?

The PSA test is a simple blood test, taken from the arm, which measures the amount of PSA protein in the blood. It is common for PSA to be found in the blood in very small concentrations. Higher levels of PSA may indicate the presence of cancer, but can also be an indicator of other prostate conditions.
PSA_Test.png
Prostate Cancer Canada graciously acknowledges the Princess Margaret Cancer Centre for sharing this image with us.
What are the benefits and limitations of the PSA test?
 
Benefits Limitations
May indicate the presence of cancer in its earliest stages. May lead to unnecessary tests and treatment.
Simple blood test (not harmful). Cannot distinguish between slow growing and advanced cancer.
Currently only test we have as red flag to indicate follow-up. The PSA test cannot diagnose prostate cancer but can tell you if there’s a problem with the prostate.


It's important to note that the PSA test is often used to monitor how someone responds to cancer treatment or to monitor disease recurrence or progression.

For more information and support:


Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive